Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: how many shares in treasury

A corp would never recognize a profit or loss in transactions involving it's own stock. Would affect the balance sheet and not the income statement.

At this point I would rather see us take on debt than to issue another 30m in shares. In fact, if you think that MMP revenue will continue at the same annual levels it seems to be a no-brainer to just finance the Crossflo deal and pay it off with future earnings.

Not trying to open a can of worms, but issuing new shares actually helps RG in a perverse kind of way. If the shares are restricted, as some have mentioned, they will not affect the current trading activity. However, when figuring ptsc's market cap, which is a calc used in RG incentives, the additional shares are counted. So to get a $400m market cap RG only needs the sp to go to 95 cents instead of the current $1.03 calc.

In the end, I sure would like to know RG's thinking on all of this.

Share
New Message
Please login to post a reply